US Pharma MarketingIsomorphic Labs receives $2.1bn for AI drug development
Isomorphic Labs has secured $2.1bn in funding to expedite its transition from developing AI models to deploying them on a larger scale. The proceeds will be used to accelerate Isomorphic Labs’ pipeline of therapeutic programmes and further develop its IsoDDE AI drug design engine. The funding will be used to support hiring by integrating AI, engineering, and drug design. Credit: Gorodenkoff / Shutterstock.com. AI drug design and development company Isomorphic Labs has secured $2.1bn in Series B funding to expedite its transition from developing innovative AI models to deploying them on a larger scale. The round was led by Thrive…
Isomorphic Labs has secured $2.1bn in funding to expedite its transition from developing AI models to deploying them on a larger scale.
Source: Pharmaceutical Technology